Arvest Investments Inc. Sells 5,650 Shares of Johnson & Johnson (NYSE:JNJ)

Arvest Investments Inc. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 21.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 21,219 shares of the company’s stock after selling 5,650 shares during the quarter. Arvest Investments Inc.’s holdings in Johnson & Johnson were worth $3,357,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Kennedy Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 18.6% during the third quarter. Kennedy Capital Management LLC now owns 20,478 shares of the company’s stock valued at $3,189,000 after purchasing an additional 3,206 shares during the last quarter. Ramirez Asset Management Inc. purchased a new position in shares of Johnson & Johnson during the third quarter valued at approximately $1,180,000. Stonebridge Capital Advisors LLC lifted its holdings in shares of Johnson & Johnson by 4.9% during the third quarter. Stonebridge Capital Advisors LLC now owns 90,302 shares of the company’s stock valued at $14,065,000 after purchasing an additional 4,247 shares during the last quarter. Pacific Center for Financial Services lifted its holdings in shares of Johnson & Johnson by 107.1% during the third quarter. Pacific Center for Financial Services now owns 1,553 shares of the company’s stock valued at $242,000 after purchasing an additional 803 shares during the last quarter. Finally, Studio Investment Management LLC lifted its holdings in shares of Johnson & Johnson by 7.8% during the third quarter. Studio Investment Management LLC now owns 26,356 shares of the company’s stock valued at $4,105,000 after purchasing an additional 1,909 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 0.2 %

Shares of NYSE JNJ opened at $145.69 on Friday. The firm’s 50-day moving average price is $147.96 and its 200-day moving average price is $153.85. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $350.63 billion, a price-to-earnings ratio of 9.08, a P/E/G ratio of 2.42 and a beta of 0.52. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business’s revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.68 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a yield of 3.40%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio is 30.92%.

Analyst Ratings Changes

JNJ has been the subject of a number of recent analyst reports. The Goldman Sachs Group initiated coverage on shares of Johnson & Johnson in a report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price objective for the company. Bank of America decreased their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 30th. Eight investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $174.07.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.